Study on the correlation of JAK2V617F mutation and cerebrovascular events in patients with myeloproliferative
neoplasms
GUO Huimei1, HE Jianhui2, LI Yunpeng3, SHANG Xuefei3, ZHOU Yun3, ZONG Wei3, PENG Yan3
1. Department of Hematology, Affiliated Hospital of Hebei University, Baoding 071000, China; 2. Department of Neurosurgery, Baoding First Central Hospital, Baoding 071000, China; 3. The First Hospital of Baoding, Baoding 071000, China
GUO Huimei, HE Jianhui, LI Yunpeng, SHANG Xuefei, ZHOU Yun, ZONG Wei, PENG Yan. Study on the correlation of JAK2V617F mutation and cerebrovascular events in patients with myeloproliferative
neoplasms[J]. Medical Reserch and Education, 2014, 31(6): 28-30.
[1] BAXTER E J, SCOTT L M, CAMPBELL P J, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases[J]. Lancet, 2005, 365 (3): 1054-1061.
[2] REIKVAM H, TIU R V. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera[J]. Leukemia, 2012, 26(4): 563-571.
[3] DE STEFANO V, ROSSI E, ZA T, et al. JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis[J]. Am J Hematol, 2011, 86(6): 526-528.
[4] CAMPBELL P J, SCOTT L M, BUCK G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study[J]. Lancet, 2005, 366: 1945-1953.
[5] LANDOLFI R, DI GENNARO L, FALANGA A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation[J]. Leukemia, 2008, 22 (11): 2020-2028.
[6] 白雪燕, 白贝贝,于小蕊, 等. 骨髓增殖性肿瘤伴发卒中的临床分析[J]. 中国卒中杂志, 2013, 8(1): 31-38.